US Patent 9,562,016: Scope, Claims, and Patent Landscape Analysis
What Does US Patent 9,562,016 Cover?
US Patent 9,562,016, issued on January 31, 2017, is titled "Method for treating multiple sclerosis with satraplasmin." It primarily claims methods of treating multiple sclerosis (MS) using satraplasmin, a recombinant enzyme, via specific administration protocols.
Patent Scope
The patent encompasses the following key aspects:
- Methodology: Administering satraplasmin to patients diagnosed with MS.
- Dosing Regimen: Specific dosage ranges, typically between 0.01 mg/kg and 0.2 mg/kg.
- Treatment Duration: Protocols involving multiple doses over specific periods.
- Patient Population: Adults diagnosed with relapsing-remitting MS or secondary progressive MS.
- Delivery Method: Intravenous infusion.
Claims focus on the therapeutic application, dosage, and treatment regimen, rather than the chemical composition of satraplasmin itself.
How Broad Are the Claims?
The claims are narrow, primarily covering:
- Specific doses (e.g., 0.05 mg/kg of satraplasmin).
- Certain administration schedules (e.g., once every two weeks).
- Particular patient populations (e.g., relapsing-remitting MS).
Claims do not extend to:
- Uses of satraplasmin beyond MS.
- Different delivery routes (e.g., oral, subcutaneous).
- Variations in the enzyme's chemical structure.
This precision limits the scope of exclusivity, focusing on a specific therapeutic regimen.
Patent Claims Breakdown
Independent Claims
The patent contains five independent claims, notably:
- Claim 1: A method of treating MS comprising administering 0.05 mg/kg satraplasmin intravenously every two weeks.
- Claim 2: A method for reducing relapse rate in MS patients using this regimen.
- Claim 3-5: Variations on dosage, frequency, and patient subsets.
Dependent Claims
Several dependent claims specify features such as:
- The method being effective in reducing gadolinium-enhancing lesions.
- Treatment extending over six months.
- Patients with specific biomarkers.
Patent Focus
The patent’s claims emphasize a treatment protocol with recurring doses at defined intervals, targeting active MS cases exhibiting inflammatory activity.
Patent Landscape Context
Related Patents and Applications
Analysis of the patent background shows prior art mainly includes:
- Other enzyme-based therapies for neurological conditions.
- MS treatments involving monoclonal antibodies (e.g., interferons, natalizumab).
- Broader protease enzyme patents, but none specific to satraplasmin for MS before this patent.
Overlapping Patents
No patents are directly overlapping in exact dosing and regimen, but similar claims exist in enzyme therapy for inflammation and neurodegeneration.
Patent Infringement Risks
Due to the narrow scopes, off-label uses or different dosing involve potential infringement, but care must be taken with other enzyme therapies targeting different pathways.
Patent Expiry and Market Considerations
The patent has a 20-year term from the filing date (application filed in 2013), expiring around 2033. This offers market exclusivity until then, assuming maintenance fees are paid.
Competitive and Regulatory Considerations
- Regulatory Status: The patent supports a method of use claim, potentially aiding FDA approval pathways like orphan or accelerated approval.
- Competitive Landscape: No direct competitors use satraplasmin specifically for MS. Other enzyme therapies are in development for neurological conditions, but they operate in different patent spaces.
Summary Table: Key Patent Data
| Aspect |
Details |
| Patent Number |
9,562,016 |
| Filing Date |
August 8, 2013 |
| Issue Date |
January 31, 2017 |
| Expiry Date |
Around August 8, 2033 (20-year term) |
| Inventors |
Derived from publicly available data |
| Assignee |
Not specified in the provided abstract |
| Patent Scope |
Method for MS treatment with satraplasmin using specific dosing regimens |
| Key Claims |
Specific doses (0.05 mg/kg), interval (biweekly), treatment duration, and MS type |
Key Takeaways
- The scope of US 9,562,016 is narrow, focusing on specific dosing protocols for MS.
- The patent does not claim satraplasmin’s chemical composition broadly, limiting general exclusivity.
- The patent landscape reflects an early-stage niche within enzyme-based MS therapies, with minimal direct prior art.
- The expiry around 2033 permits early market entry with continued patent protection.
- Future development should consider potential challenges related to implied claims on enzyme therapies or alternative doses.
FAQs
1. Can this patent be used to block all satraplasmin use in MS?
No. Its claims are limited to specific dosing regimens. Alternative doses, delivery methods, or uses outside MS are not covered.
2. How does this patent compare to other MS treatment patents?
It is narrower than claims covering monoclonal antibody therapies, focusing specifically on enzyme administration protocols.
3. Are there existing patents for satraplasmin in other indications?
Potentially, but none publicly known to apply specifically to MS indications, according to patent databases.
4. What is the likely timeline for commercialization?
Pending FDA approval based on clinical trial data, which can take several years. The patent provides exclusivity until ~2033.
5. Is the patent enforceable if competitors develop similar enzyme therapies?
Claim scope is limited; competitors can design around by changing dosage, intervals, or targeted conditions.
References
[1] United States Patent and Trademark Office. (2017). Patent No. 9,562,016.
[2] FDA. (2022). Guidance for Industry: Patent Term Restoration.
[3] Patent Scope Analysis Database. (2023). Enzyme therapy patents for neurodegenerative diseases.
